Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Malath Makhay"'
Autor:
Namita Goyal, Nathan P. Staff, Malath Makhay, Bjorn Oskarsson, Seiichi Yasui, Richard Bedlack, Emelia Klonowski, John Turnbull, Nicholas J. Maragakis, Benjamin Rix Brooks, Jenny A Meyer, Kazuko Matsuda, Lorne Zinman, Cynthia Bodkin, Nicholas Olney, Samuel Maiser, Angela Genge
Publikováno v:
Neurodegenerative disease management. 11(6)
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with motor neuron loss as a defining feature. Despite significant effort, therapeutic breakthroughs have been modest. MN-166 (ibudilast) has demonstrated neuroprotective action by var
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5c8ba61f68014d187443a87f71f6e15
https://pubmed.ncbi.nlm.nih.gov/34816762
https://pubmed.ncbi.nlm.nih.gov/34816762
Publikováno v:
Journal of Asthma. 49:1071-1078
The number of hospitalizations or deaths due to asthma, most of which result from acute exacerbations of asthma, has remained the same for the past 20 years. MN-221 (bedoradrine sulfate) is a novel, highly selective beta2- (β2-) adrenergic agonist a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::701976b1442243ed1e787c063235b0a8
https://doi.org/10.3109/02770903.2012.729631
https://doi.org/10.3109/02770903.2012.729631
Autor:
Malath Makhay, Kazuko Matsuda, Geoffrey O'Brien, Ian Ferguson, Lawrence M. Lewis, Luis M. Lovato, Yuichi Iwaki, Stacey L. House
Publikováno v:
Respiratory medicine. 109(10)
Many patients with acute exacerbation of asthma are non-responders to inhaled β-adrenergic agonists. The goal of this study was to evaluate the safety and efficacy of intravenous bedoradrine (MN-221), a highly selective β2-adrenergic agonist, as ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::148d7f5f2d3b5099cd649f4e6ec90ce9
https://pubmed.ncbi.nlm.nih.gov/26324315
https://pubmed.ncbi.nlm.nih.gov/26324315
Autor:
Scott C. Harvey, Isaac Veinbergs, Kimberly E. Vanover, Carl-Magnus A. Andersson, Allan K. Uldam, David M. Weiner, Fabrice Piu, Bo-Ragner Tolf, Andria L. Del Tredici, Mark A. Geyer, Thomas Son, Robert E. Davis, Malath Makhay, Thomas R. Ott, Mark R. Brann, Jelveh Lameh, Ethan S. Burstein, Nathalie Schlienger, Hans H. Schiffer, Susan B. Powell, Luis R. Gardell, Mikkel B. Thygesen
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 317:910-918
The in vitro and in vivo pharmacological properties of N -(4-fluorophenylmethyl)- N -(1-methylpiperidin-4-yl)- N ′-(4-(2-methylpropyloxy)phenylmethyl)carbamide (2 R ,3 R )-dihydroxybutanedioate (2:1) (ACP-103) are presented. A potent 5-hydroxytrypt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e7de0fc0198101248cda15fb4bff3cc
https://doi.org/10.1124/jpet.105.097006
https://doi.org/10.1124/jpet.105.097006
Autor:
Stefania Risso Bradley, Robert E. Davis, Tracy Spalding, Uli Hacksell, Kimberly E. Vanover, Malath Makhay, Carl-Magnus A. Andersson, Bo-Ragnar Tolf, Henriette Kold, Thomas Son, Isaac Veinbergs, Mark R. Brann, David M. Weiner, Scott C. Harvey
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 310:943-951
The primary purpose of the present series of experiments was to characterize the in vitro and in vivo pharmacology profile of 2-(4-methoxy-phenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride (AC-90179), a selective seroton
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f03c393a0442791287ab5db3f9b886ec
https://doi.org/10.1124/jpet.104.066688
https://doi.org/10.1124/jpet.104.066688
Autor:
Kimberly E, Vanover, David M, Weiner, Malath, Makhay, Isaac, Veinbergs, Luis R, Gardell, Jelveh, Lameh, Andria L, Del Tredici, Fabrice, Piu, Hans H, Schiffer, Thomas R, Ott, Ethan S, Burstein, Allan K, Uldam, Mikkel B, Thygesen, Nathalie, Schlienger, Carl Magnus, Andersson, Thomas Y, Son, Scott C, Harvey, Susan B, Powell, Mark A, Geyer, Bo-Ragner, Tolf, Mark R, Brann, Robert E, Davis
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 317(2)
The in vitro and in vivo pharmacological properties of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103) are presented. A potent 5-hydroxytryptamine (5-HT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f7de06e08d49abdd0658b75c89ccec8a
https://pubmed.ncbi.nlm.nih.gov/16469866
https://pubmed.ncbi.nlm.nih.gov/16469866
Autor:
E, Vanover Kimberly, C, Harvey Scott, Thomas, Son, Risso, Bradley Stefania, Henriette, Kold, Malath, Makhay, Isaac, Veinbergs, A, Spalding Tracy, M, Weiner David, Magnus, Andersson Carl, Bo-Ragnar, Tolf, R, Brann Mark, Uli, Hacksell, E, Davis Robert
Publikováno v:
The Journal of Pharmacology and Experimental Therapeutics; September 2004, Vol. 310 Issue: 3 p943-51, 9p